Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy …
MP Dubé, JH Stein, JA Aberg… - Clinical Infectious …, 2003 - academic.oup.com
Dyslipidemia is a common problem affecting HIV-infected patients receiving antiretroviral
therapy. Since publication of preliminary guidelines in 2000 [1], numerous studies have …
therapy. Since publication of preliminary guidelines in 2000 [1], numerous studies have …
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel
M Schambelan, CA Benson, A Carr… - JAIDS Journal of …, 2002 - journals.lww.com
Objective: Alterations in glucose and lipid metabolism, lactic acidemia, bone disorders, and
abnormal body fat distribution have been recognized recently as frequent complications …
abnormal body fat distribution have been recognized recently as frequent complications …
Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection
JS Tucker, MA Burnam, CD Sherbourne… - The American journal of …, 2003 - Elsevier
PURPOSE: Mental health and substance use problems are common among patients
infected with human immunodeficiency virus (HIV) and may impede adherence to …
infected with human immunodeficiency virus (HIV) and may impede adherence to …
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: the panel on clinical practices for treatment of HIV
M Dybul, AS Fauci, JG Bartlett, JE Kaplan… - Annals of internal …, 2002 - acpjournals.org
The availability of an increasing number of antiretroviral agents and the rapid evolution of
new information have introduced substantial complexity into treatment regimens for persons …
new information have introduced substantial complexity into treatment regimens for persons …
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
Levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-
c), and high-density lipoprotein cholesterol (HDL-c), as well as the TC: HDL-c ratio, were …
c), and high-density lipoprotein cholesterol (HDL-c), as well as the TC: HDL-c ratio, were …
HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management
A Carr - Aids, 2003 - journals.lww.com
HIV lipodystrophy is a heterogeneous syndrome, which has yet to be objectively defined,
comprising peripheral lipoatrophy, central fat accumulation and lipomata, along with …
comprising peripheral lipoatrophy, central fat accumulation and lipomata, along with …
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
E Martínez, JA Arnaiz, D Podzamczer… - … England Journal of …, 2003 - Mass Medical Soc
Background We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a
protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in …
protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in …
Lipodystrophy in human immunodeficiency virus-infected patients
D Chen, A Misra, A Garg - The Journal of Clinical Endocrinology …, 2002 - academic.oup.com
Human immunodeficiency virus (HIV) infection is a major global health problem. Recently,
combination therapy including HIV-1 protease inhibitors (PIs) has dramatically improved the …
combination therapy including HIV-1 protease inhibitors (PIs) has dramatically improved the …
Toxicity of antiretroviral therapy and implications for drug development
A Carr - Nature reviews Drug discovery, 2003 - nature.com
The toxicity of antiretroviral therapy is an increasingly important issue in the management of
patients with human immunodeficiency virus (HIV). With sustained major declines in …
patients with human immunodeficiency virus (HIV). With sustained major declines in …
Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction
Background Lipoatrophy and/or central fat gain are observed frequently in patients on
antiretroviral therapy (ART). Both are assumed to be antiretroviral adverse drug reactions …
antiretroviral therapy (ART). Both are assumed to be antiretroviral adverse drug reactions …